It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Quiescence in stem cells is traditionally considered as a state of inactive dormancy or with poised potential. Naive mouse embryonic stem cells (ESCs) can enter quiescence spontaneously or upon inhibition of MYC or fatty acid oxidation, mimicking embryonic diapause in vivo. The molecular underpinning and developmental potential of quiescent ESCs (qESCs) are relatively unexplored. Here we show that qESCs possess an expanded or unrestricted cell fate, capable of generating both embryonic and extraembryonic cell types (e.g., trophoblast stem cells). These cells have a divergent metabolic landscape comparing to the cycling ESCs, with a notable decrease of the one-carbon metabolite S-adenosylmethionine. The metabolic changes are accompanied by a global reduction of H3K27me3, an increase of chromatin accessibility, as well as the de-repression of endogenous retrovirus MERVL and trophoblast master regulators. Depletion of methionine adenosyltransferase Mat2a or deletion of Eed in the polycomb repressive complex 2 results in removal of the developmental constraints towards the extraembryonic lineages. Our findings suggest that quiescent ESCs are not dormant but rather undergo an active transition towards an unrestricted cell fate.
Stem cell quiescence is generally considered as an inactive state with poised potential. Here, Khoa et al. find that quiescent embryonic stem cells actively maintain a dynamic reservoir of cells with unrestricted cell fate that converges on S-adenosylmethionine and H3K27me3 status.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Southern California, Department of Medicine, Norris Comprehensive Cancer Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Michigan Medical School, Department of Molecular and Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
2 University of Southern California, Department of Medicine, Norris Comprehensive Cancer Center, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
3 University of Michigan Medical School, Department of Molecular and Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
4 Peking University Third Hospital, Institute of Medical Innovation and Research, Beijing, China (GRID:grid.411642.4) (ISNI:0000 0004 0605 3760)
5 University of Michigan Medical School, Department of Human Genetics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
6 University of Michigan, Department of Ophthalmology & Visual Sciences, W.K. Kellogg Eye Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347)
7 Beaumont Hospital, Wayne, Wayne, USA (GRID:grid.414575.6) (ISNI:0000 0004 0424 3608)